Microbiome Therapeutics Market Outlook:
Microbiome Therapeutics Market size was valued at USD 526.07 million in 2025 and is expected to reach USD 11.14 billion by 2035, registering around 35.7% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of microbiome therapeutics is assessed at USD 695.1 million.
The market growth is driven by increasing proportion of several diseases comprising inflammatory bowel disease (IBD), obesity, allergic disorders, and so on caused by dysbiosis of microbiota in the gut across the world. For instance, currently, there are nearly 11 million individuals have been suffering from inflammatory bowel disease (IBD) across the globe. Further, the growing concerns amongst individuals about the beneficial microorganisms in the human body, growing age, and unhealthy lifestyle patterns will boost the global market size.
In addition, radically rising investments in microbiome modulators, and escalating collaboration between major key players for producing novel microbiome therapeutics will fuel the microbiome therapeutics market growth. For instance, on February 1, 2023, The University of Texas MD Anderson Cancer Center announced a strategic partnership with the global biopharma institute Federation Bio to rationally produce a novel microbiome treatment for immunotherapy-resistant cancer patients. Additionally, surging awareness regarding microbiome therapeutics will spur the market expansion.
